InterCure Proposes 5-to-1 Reverse Split to Avert Nasdaq Delisting

summarizeSummary

InterCure has called a shareholder vote on a 5-to-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price rule, warning that failure to approve will likely result in delisting.

check_boxKey Events · Corporate Governance and Compliance · INCR

• Reverse Split Proposal

  Shareholders will vote on a 5-to-1 reverse stock split at an August 12, 2026 meeting, with a record date of July 29, 2026.

• Nasdaq Compliance Deadline

  The company received a minimum bid price deficiency notice on February 25, 2026, and has until August 24, 2026 to regain compliance or face delisting.

• Delisting Risk

  If the reverse split is not approved, the company warns its shares will likely be delisted to the over-the-counter market, reducing liquidity and institutional access.

• Board Recommendation

  The board unanimously recommends voting FOR the reverse split, stating it is in the best interests of the company and shareholders.

auto_awesomeAnalysis · INCR · Life Sciences

To address a Nasdaq deficiency notice received in February—after its shares traded below $1.00 for 30 consecutive business days—InterCure is asking shareholders to approve a 5-to-1 reverse stock split at an August 12 meeting. Without the reverse split, the stock will likely be delisted to the over-the-counter market, a move that would reduce liquidity, limit institutional investor access, and make future capital raises more difficult. The board unanimously recommends approval, framing it as essential to maintaining the Nasdaq listing that supports financing and shareholder liquidity.